Sunshine BiopharmaSBFM
About: Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.
Employees: 44
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
24% more capital invested
Capital invested by funds: $90K [Q2] → $111K (+$21.3K) [Q3]
1.72% more ownership
Funds ownership: 1.15% [Q2] → 2.87% (+1.72%) [Q3]
9% less funds holding
Funds holding: 11 [Q2] → 10 (-1) [Q3]
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for SBFM.